Q4 2025 · 13F-HR
TCG Crossover Management, LLCholdings as filed
Filed 2026-02-17 · accession 0001214659-26-001871
$3.02B
Reported value
43
Positions
2025-12-31
Period end
The Brief · TCG Crossover Management, LLC · Q4 2025
AI · grounded in 13F
TCG Crossover Management, LLC closed its position in Tourmaline Bio Inc TRML, reducing exposure by $62.7M. The fund established new positions in Monte Rosa Therapeutics Inc GLUE for $72.5M, Biohaven Ltd for $52.3M, and Immunovant Inc IMVT for $42.2M. Additionally, the manager increased share counts in Spyre Therapeutics Inc SYRE by 72.7% and Rapt Therapeutics Inc RAPT by 57.8%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 00370M103 | ABVX | ABIVAX SA AMERICAN DEPOSITARY SHARES | $959.0M | 31.7% | 7,111,596 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $208.4M | 6.90% | 5,868,162 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $152.4M | 5.04% | 3,670,206 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $113.1M | 3.74% | 12,762,094 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $107.2M | 3.55% | 4,286,480 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $90.3M | 2.99% | 4,615,144 | Common | SOLE |
| 75382E208 | RAPT | RAPT THERAPEUTICS INC | $87.5M | 2.89% | 2,582,408 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $76.2M | 2.52% | 2,898,103 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $75.4M | 2.50% | 6,243,812 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $74.5M | 2.47% | 12,362,205 | Common | SOLE |
| 61225M102 | GLUE | MONTE ROSA THERAPEUTICS INC | $72.5M | 2.40% | 4,622,151 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $69.7M | 2.31% | 5,740,231 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $69.1M | 2.29% | 1,676,624 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $65.3M | 2.16% | 3,572,335 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $64.0M | 2.12% | 920,857 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $62.3M | 2.06% | 1,900,582 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $59.4M | 1.97% | 5,250,000 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA TECHNOLOGIES INC | $59.0M | 1.95% | 1,710,084 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $52.3M | 1.73% | 4,631,317 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $42.2M | 1.40% | 1,660,933 | Common | SOLE |
| 50015M109 | KOD | KODIAK SCIENCES INC | $40.4M | 1.34% | 1,445,538 | Common | SOLE |
| H0036K147 | ADCT | ADC THERAPEUTICS SA | $40.2M | 1.33% | 11,390,175 | Common | SOLE |
| 50180M108 | LBRX | LB PHARMACEUTICALS INC | $38.8M | 1.29% | 1,745,015 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $37.5M | 1.24% | 2,452,138 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $34.8M | 1.15% | 436,473 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $32.2M | 1.06% | 1,181,841 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS HOLDING CO LLC | $31.6M | 1.05% | 2,666,216 | Common | SOLE |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $27.2M | 0.90% | 3,220,186 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $24.7M | 0.82% | 1,789,617 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $21.5M | 0.71% | 2,088,392 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $20.5M | 0.68% | 650,000 | Common | SOLE |
| 91678A107 | UPB | UPSTREAM BIO INC | $20.2M | 0.67% | 743,886 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $18.4M | 0.61% | 3,033,560 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $16.8M | 0.56% | 717,347 | Common | SOLE |
| 014442107 | ALEC | ALECTOR INC | $15.6M | 0.52% | 10,000,000 | Common | SOLE |
| 61023L207 | MNPR | MONOPAR THERAPEUTICS INC | $9.3M | 0.31% | 141,915 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $8.8M | 0.29% | 483,000 | Common | SOLE |
| 578784100 | MAZE | MAZE THERAPEUTICS INC | $7.2M | 0.24% | 173,816 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $4.9M | 0.16% | 62,049 | Common | SOLE |
| 04746L203 | LONA | Athira Pharma, Inc. | $3.3M | 0.11% | 464,398 | Common | SOLE |
| 500946108 | KRRO | KORRO BIO INC | $3.3M | 0.11% | 416,301 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $2.9M | 0.09% | 316,195 | Common | SOLE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $1.8M | 0.06% | 2,676,580 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.